X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
YCANTH (formerly VP-10) is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin delivered via a single-use applicator that allows for precise topical dosing and targeted administration for the treatment of Common Warts.
Lead Product(s): Cantharidin
Therapeutic Area: Infections and Infectious Diseases Product Name: Ycanth
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
VP-315 (ruxotemitide)is a potential first-in-class oncolytic peptide immunotherapy administered directly into a tumor to induce immunogenic cell death. It is under phase 2 clinical development for the treatment of Basal Cell Carcinoma.
Lead Product(s): Ruxotemitide
Therapeutic Area: Oncology Product Name: VP-315
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2024
Details:
YCANTH (formerly VP-10) is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin delivered via a single-use applicator that allows for precise topical dosing and targeted administration for the treatment of Common Warts.
Lead Product(s): Cantharidin
Therapeutic Area: Infections and Infectious Diseases Product Name: Ycanth
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2024
Details:
TO-208 previously known as VP-102 is a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). It is being evaluated in phase 3 clinical trials for the treatment of Molluscum Contagiosum.
Lead Product(s): Cantharidin
Therapeutic Area: Infections and Infectious Diseases Product Name: TO-208
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2023
Details:
The net proceeds will support the commercialization of Ycanth topical solution, a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin and the first and only FDA-approved treatment for molluscum contagiosum.
Lead Product(s): Cantharidin
Therapeutic Area: Infections and Infectious Diseases Product Name: Ycanth
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: OrbiMed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing July 26, 2023
Details:
YCANTH™ (cantharidin) topical solution is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin (0.7% w/v) delivered via a single-use applicator, which is used for Molluscum Contagiosum.
Lead Product(s): Cantharidin
Therapeutic Area: Infections and Infectious Diseases Product Name: Ycanth
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2023
Details:
VP-315 (ruxotemitide, formerly known as LTX 315) is a potential first-in-class oncolytic peptide immunotherapy administered directly into a tumor to induce immunogenic cell death, which may offer a non-surgical option for patients suffering from skin cancer.
Lead Product(s): Ruxotemitide
Therapeutic Area: Oncology Product Name: VP-315
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2023
Details:
VP-102 (cantharidin) activates or releases neutral ser- ine proteases that cause degeneration of the desmosmal plaque, leading to detachment of tonofilaments from des-mosomes. It is being developed for for the treatment of molluscum contagiosum.
Lead Product(s): Cantharidin
Therapeutic Area: Infections and Infectious Diseases Product Name: VP-102
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2023
Details:
Verricaʼs lead product candidate, VP-102, is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin delivered via a single-use applicator that allows for precise topical dosing and targeted administration.
Lead Product(s): Cantharidin
Therapeutic Area: Infections and Infectious Diseases Product Name: VP-102
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies LLC
Deal Size: $32.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 21, 2023
Details:
VP-102, is a proprietary drug-device combination product that contains cantharidin (0.7% w/v) delivered via a singleuse applicator that allows for precise topical dosing and targeted administration. It is being developed for molluscum contagiosum.
Lead Product(s): Cantharidin
Therapeutic Area: Infections and Infectious Diseases Product Name: VP-102
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
